 | Up a level |
Hoeper, M. M., Ghofrani, H. -A., Benza, R. L., Corris, P. A., Gibbs, S., Klinger, J. R., Langleben, D., McLaughlin, V. V., Peacock, A., Rosenkranz, S., Vonk-Noordegraaf, A., White, J., Kleinjung, F., Meier, C. and Simonneau, G. (2017). Rationale And Design Of The Replace Trial: Riociguat Replacing Phosphodiesterase 5 Inhibitor (pde5i) Therapy Evaluated Against Continued Pde5i Therapy In Patients With Pulmonary Arterial Hypertension (pah). Am. J. Respir. Crit. Care Med., 195. NEW YORK: AMER THORACIC SOC. ISSN 1535-4970
Klose, H., Gall, H., Ghofrani, H., Gruenig, E., Humbert, M., Simonneau, G., Halank, M., Langleben, D., Snijder, R. J., Escribano, P., Mielniczuk, L. M., Lange, T., Vachiery, J., Wirtz, H., Helmersen, D. S., Tsangaris, I., Barbera, J. A., Pepke-Zaba, J., Boonstra, A., Rosenkranz, S., Ulrich, S., Mascherbauer, R., Delcroix, M., Jansa, P., Gomez Sanchez, M. A., Klotsche, J., Meier, C., Pittrow, D. and Hoeper, M. M. (2018). Riociguat for the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Update from the EXPERT Registry. Am. J. Respir. Crit. Care Med., 197. NEW YORK: AMER THORACIC SOC. ISSN 1535-4970